Sigyn Therapeutics appoints Jeremy Ferrell as CFO, effective March 9, 2022

Sigyn Therapeutics, Inc.

Jeremy Ferrell (CPA, MBA) appointed CFO; base salary $250,000/year, annual bonus up to 40%.
Stock options for up to 600,000 shares at grant date market price; 25% vest at grant, rest over 3 years.
Employment agreement is indefinite duration, at-will; includes standard terms.
Ferrell has 25+ years finance experience; most recently CFO at Miku, Inc.

item 1.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jeremy Ferrell

Chief Financial Officer

SIGY · Sigyn Therapeutics, Inc.

Effective: 2022-03-09
Filed: March 9, 2022, 6:59 PM ET

The Board of Directors of Sigyn Therapeutics, Inc. (“the Company”) appointed Jeremy Ferrell, CPA, MBA as Chief Financial Officer (“CFO”), effective March 9, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeremy Ferrell was appointed as Chief Financial Officer at Sigyn Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

The Board of Directors of Sigyn Therapeutics, Inc. (“the Company”) appointed Jeremy Ferrell, CPA, MBA as Chief Financial Officer (“CFO”), effective March 9, 2022.

View on SEC.gov

Sigyn Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-006402

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.